Endoscopic submucosal dissection for malignant esophageal lesions

15Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The incidence of esophageal cancer has been increasing while the prognosis remains very poor. Endoscopic submucosal dissection (ESD) was developed in Japan for en bloc resection of early gastric cancer with excellent results. The use of ESD in early squamous cell cancer (SCC) of the esophagus in Japan has been increasing with long-term results comparable to those in early gastric cancer. The use of ESD in Barrett's neoplasia in western countries has been challenged by the low complete resection rates and the risk of metachronous lesions from surrounding non-dysplastic Barrett's epithelium. Efforts to combine ESD with other treatment modalities such as radiofrequency ablation in Barrett's neoplasia and chemoradiation in SCC appear to be promising. The use of steroid therapy (local or systemic) has been demonstrated to prevent post-ESD stenosis, which is the most common complication after esophageal ESD. © Springer Science+Business Media 2014.

Author supplied keywords

Cite

CITATION STYLE

APA

Hammad, H., Kaltenbach, T., & Soetikno, R. (2014). Endoscopic submucosal dissection for malignant esophageal lesions. Current Gastroenterology Reports. Current Medicine Group LLC 1. https://doi.org/10.1007/s11894-014-0386-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free